- Home
- ANL vs CLNN Comparison
ANL vs CLNN Comparison
Compare ANL & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- CLNN
- Stock Information
- Founded
- ANL 2004
- CLNN 2012
- Country
- ANL Cayman Islands
- CLNN United States
- Employees
- ANL N/A
- CLNN N/A
- Industry
- ANL
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- CLNN Health Care
- Exchange
- ANL Nasdaq
- CLNN Nasdaq
- Market Cap
- ANL 61.8M
- CLNN 60.3M
- IPO Year
- ANL 2023
- CLNN N/A
- Fundamental
- Price
- ANL $1.66
- CLNN $8.67
- Analyst Decision
- ANL Hold
- CLNN Strong Buy
- Analyst Count
- ANL 1
- CLNN 6
- Target Price
- ANL N/A
- CLNN $32.67
- AVG Volume (30 Days)
- ANL 7.7K
- CLNN 152.0K
- Earning Date
- ANL 11-04-2025
- CLNN 11-12-2025
- Dividend Yield
- ANL N/A
- CLNN N/A
- EPS Growth
- ANL N/A
- CLNN N/A
- EPS
- ANL N/A
- CLNN N/A
- Revenue
- ANL N/A
- CLNN $286,000.00
- Revenue This Year
- ANL N/A
- CLNN N/A
- Revenue Next Year
- ANL N/A
- CLNN $1,363.77
- P/E Ratio
- ANL N/A
- CLNN N/A
- Revenue Growth
- ANL N/A
- CLNN N/A
- 52 Week Low
- ANL $1.10
- CLNN $2.28
- 52 Week High
- ANL $3.89
- CLNN $11.06
- Technical
- Relative Strength Index (RSI)
- ANL 46.43
- CLNN 56.04
- Support Level
- ANL $1.60
- CLNN $8.02
- Resistance Level
- ANL $1.73
- CLNN $9.43
- Average True Range (ATR)
- ANL 0.08
- CLNN 1.16
- MACD
- ANL -0.01
- CLNN -0.14
- Stochastic Oscillator
- ANL 43.08
- CLNN 36.48
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.